Aethlon ( (AEMD) ) has released its Q2 earnings. Here is a breakdown of the information Aethlon presented to its investors.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Aethlon Medical, Inc., a company focused on developing therapeutic products for cancer and life-threatening infectious diseases, has released its financial results for the fiscal second quarter ended September 30, 2024, along with a corporate update. The company has made significant progress in its oncology trials in Australia, enrolling the first two patients in a safety, feasibility, and dose-finding study of its Hemopurifier® for patients with solid tumors unresponsive to anti-PD-1 antibodies. Additionally, Aethlon has received ethics committee approvals in India and continues to expand its clinical trials. Financially, the company reported a cash balance of $6.9 million, with a net loss of $2.8 million for the quarter, a decrease from the previous year, attributed to strategic cost-cutting measures. Operational efficiencies were achieved through reduced professional fees and resource optimization, despite increased payroll costs due to severance agreements. Looking ahead, Aethlon’s management remains optimistic about the ongoing oncology trials, emphasizing their potential to inform future efficacy studies and the broader application of the Hemopurifier in cancer and infectious disease treatments.
